GlaxoSmithKline (GSK) has discontinued enrolment into its phase III trial of the HIV entry inhibitor, aplaviroc [GW 873140]

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1076, 2005-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GlaxoSmithKline's candidate paediatric pneumococcal vaccine GSK 1024850A [Synflorix] has the potential to offer increased protection

By  

Inpharma, Vol. 1, Iss. 1643, 2008-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline (GSK), in consultation with Health Canada, has issued a precautionary recall of one lot of Infanrix Hexa

By  

Reactions Weekly, Vol. 1, Iss. 1428, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline (GSK) has asked government healthcare officials from several nations for opinions on which investigational drugs should be prioritised

By  

Inpharma, Vol. 1, Iss. 1646, 2008-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

GlaxoSmithKline (GSK) advises that, as new data show an interaction between lamotrigine and oral contraceptives (OCs)

By  

Reactions Weekly, Vol. 1, Iss. 1062, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Alexza Pharmaceuticals has announced that it has completed enrolment in its second phase III trial with loxapine

By  

Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite